The law offices of frank r. cruz announces investigation of acelrx pharmaceuticals, inc. (acrx) on behalf of investors
Los angeles--(business wire)--the law offices of frank r. cruz announces an investigation of acelrx pharmaceuticals, inc. (“acelrx” or the “company”) (nasdaq: acrx) on behalf of investors concerning the company’s possible violations of federal securities laws. if you are a shareholder who suffered a loss, click here to participate. acelrx is a pharmaceutical company that develops therapies for the treatment of acute pain. one of its lead product candidates is dsuvia, which has been approved by the u.s. food and drug administration (“fda”) for the management of acute pain in adults that is severe enough to require an opioid analgesic in certified medically supervised healthcare settings. on february 16, 2021, acelrx disclosed that it had received a warning letter from the fda concerning promotional claims for dsuvia. specifically, the fda concluded that certain of acelrx’s promotional communications “make false or misleading claims and representations about the risks and efficacy of dsuvia,” and “[t]hus . . . misbrand dsuvia within the meaning of the federal food, drug and cosmetic act (fd&c act) and make its distribution violative.” on this news, acelrx’s stock price fell $0.21 per share, or 8.37%, to close at $2.30 per share on february 16, 2021, thereby injuring investors. follow us for updates on twitter: twitter.com/frc_law. if you purchased acelrx securities, have information or would like to learn more about these claims, or have any questions concerning this announcement or your rights or interests with respect to these matters, please contact frank r. cruz, of the law offices of frank r. cruz, 1999 avenue of the stars, suite 1100, los angeles, california 90067 at 310-914-5007, by email to info@frankcruzlaw.com, or visit our website at www.frankcruzlaw.com. if you inquire by email please include your mailing address, telephone number, and number of shares purchased. this press release may be considered attorney advertising in some jurisdictions under the applicable law and ethical rules.
ACRX Ratings Summary
ACRX Quant Ranking
You've reached your free article limit.
Want To Read More Articles?
See what it all means for your stocks with premium tools
Stockprices is a weekly video covering what moved markets
this week, featuring a panel of Stockprices editors. It is published by the
close of trading on Fridays. Hosted by Nathaniel E. Baker, contributing editor,
and featuring: Aaron Task, VP Contributor Content and co-host Stockprices's Alpha
Trader podcast; Brad Olesen, VP News; Steve Alpher, Managing Editor News, co-host
Alpha Trader.
Unsubscribe From All
You successfully activated
“Only Essentials”
Confirm Upgrade
Your subscription will be moved to the annual plan. Service will automatically renew unless cancelled. No Refunds. Click upgrade to confirm.
Stockprices uses Plaid to connect you account
Connect effortlessly
Plaid lets you securely connect your financial accounts in seconds
Your data belongs to you
Plaid doesn't sell personal info, and will only use it with your permission